Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Biomarkers of progression and risk stratification in asymptomatic Waldenström’s macroglobulinemia

Mark Bustoros • 27 Sep 2023
IMS 2023
Lymphoma Multiple Myeloma Rare Diseases Waldenström’s Macroglobulinemia

Mark Bustoros, MD, Weill Cornell Medicine, New York City, NY, discusses four biomarkers associated with an increased risk of disease progression in patients with asymptomatic Waldenström’s macroglobulinemia (WM). Dr Bustoros elaborates on a calculator that has been developed and integrates these independent risk factors, allowing patients to be risk stratified into various categories. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mark Bustoros

3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
1:11
Advances that have been made in the molecular characterization of multiple myeloma
Mark Bustoros • 27 Sep 2023
1:50
Molecular characteristics of extramedullary myeloma
Mark Bustoros • 27 Sep 2023
1:30
Evolution in myeloma therapy
Mark Bustoros • 14 Oct 2021

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:46
The urgency of diagnosing and treating patients with Castleman disease
Karthik Ramasamy • 28 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals